openPR Logo
Press release

Benign Prostatic Hyperplasia Therapeutics Development Pipeline Overview for H1 2017

06-05-2017 03:53 PM CET | Health & Medicine

Press release from: RNR Market Research

Benign Prostatic Hyperplasia pipeline

Benign Prostatic Hyperplasia pipeline

2017 Benign Prostatic Hyperplasia pipeline market report of on global industry analysis and opportunity assessment H1 report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010746

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

H1 Benign Prostatic Hyperplasia pipeline companies are Addex Therapeutics Ltd, AndroScience Corp, Aphios Corp, BCWorld Pharm Co Ltd, Biolab Farmaceutica Ltda, Chong Kun Dang Pharmaceutical Corp, Curadis GmbH, Dongkook Pharmaceutical Co Ltd, GL Pharm Tech Corp, Hanmi Pharmaceuticals Co Ltd, Health Ever Bio-Tech Co Ltd, Jeil Pharmaceutical Co Ltd, Kaken Pharmaceutical Co Ltd, MEI Pharma Inc, Meiji Seika Pharma Co Ltd, Mezzion Pharma Co Ltd, Monosol Rx LLC, Nymox Pharmaceutical Corp, Ono Pharmaceutical Co Ltd, OPKO Health Inc, SK Chemicals Co Ltd, SOM Biotech SL, Sophiris Bio Inc, Vantia Therapeutics, XuanZhu Pharma Co Ltd, Yungjin Pharm Co Ltd.

Drug Profiles of ADX-68692, ASC-JM.X2, AUS-131, BCWPE-004, BL-214, CR-1447, fadanafil, fedovapagon, fexapotide triflutate, KKM-1202 , L-1AD3, MCS-2, NCE-403, ONO-8430506, S-0131632, S-40542, SOM-2391, SOM-2393, tadalafil, talaporfin sodium, tamsulosin hydrochloride CR, tamsulosin hydrochloride DR, tertomotide, topsalysin, TT-701, udenafil, YOB-1604.

Purchase this research report Direct from http://www.reportsnreports.com/purchase.aspx?name=1020029

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Inquire more on this Research Report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1020029

List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

About Us:
ReportsnReports.com is single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help in purchase decision by mapping your information needs with our huge collection of reports.

2nd floor, metropole,
Next to inox theatre,
Bund garden road, Pune-411001.
+ 1 888 391 5441
sales@rnrmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Benign Prostatic Hyperplasia Therapeutics Development Pipeline Overview for H1 2017 here

News-ID: 564422 • Views:

More Releases from RNR Market Research

Emerging Trends Exosome Diagnostics and Therapeutics Market Dominated by Evox Th …
An exosome diagnostic and therapeutic study approach represents the opportunity to expand and develop the liquid biopsy market, a growing sector in cancer diagnostics. Once they reach the recipient cells, cytoplasmic ingredients can alter their biology. Access Sample Papers of Exosome Diagnostics and Therapeutics Market with 248 Pages and 6 Company Profiles Now at http://www.rnrmarketresearch.com/contacts/request-sample?rname=1529771 . Growth in exosome diagnostic and therapeutic market in these regions attributes to the technological advancement in
17.8% CAGR for Care Management Solutions Market - Regions Like North America and Europe Drives the Growth
17.8% CAGR for Care Management Solutions Market - Regions Like North America and …
Key care management solutions market players are Allscripts Healthcare Solutions, Inc. (U.S.), TriZetto Corporation (U.S.), Phytel Inc. (U.S.), EXL Healthcare (U.S.), AxisPoint Health (U.S.), Wellcentive, Inc. (U.S.), Medecision, Inc. (U.S.), ZeOmega Inc. (U.S.), i2i Systems, Inc. (U.S.), HealthSmart Holdings, Inc. (U.S.), Pegasystems Inc. (U.S.), Epic Corporation Inc. (U.S.), and Harmony Information Systems, Inc. (U.S.) Download Brochure of Care Management Solutions Market spread across 191 pages, Profiling 15 Companies and Supported with
Global 5K Display Resolution Market: 2019 Industry Analysis, Size, Trends, Growth and Forecast 2025 | Canon Inc, Samsung Electronics, Sony Corporation, LG Electronics Inc, Sharp Corporation, Philips, HP, Others
Global 5K Display Resolution Market: 2019 Industry Analysis, Size, Trends, Growt …
This report presents the worldwide 5K Display Resolution Market size (value, production and consumption), splits the breakdown (data status 2014-2018 and forecast to 2025), by manufacturers, region, type and application. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis. Global 5K Display Resolution Market Report including definitions, classifications, applications and
Dialyzers Market 2019-2025: Global Consumption Value, Sales and Key Companies Pr …
The global Dialyzers Market 2019 research is a professional and in-depth study on the current state of the industry and provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. This report presents the worldwide Dialyzers Market size (value, production and consumption), splits the breakdown (data status 2014-2018 and forecast to 2025), by manufacturers, region, type and application. This study also analyzes the market status, market

All 5 Releases


More Releases for Benign

Benign Prostatic Hyperplasia Therapeutics Market Clinical Survey Report 2020
The Benign Prostatic Hyperplasia Therapeutics Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Click the link
Benign prostatic hyperplasia: BPH drugs versus Dr Allen’s Device
The Global Treatment Market of Benign prostatic hyperplasia (BPH) was valued at $10,688.72 million in 2017 and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. Thermobalancing therapy with Dr Allen’s Device was patented by the United States Patent and Trademark Office. Over a decade, thousands of men with BPH used or are using this non-invasive and side-effects free Dr Allen’s Device.
Cold Plasma Market Benign Rate by 2025
Global Cold Plasma Market: Snapshot Cold plasma, additionally called non-warm plasma or non-balance plasma, is a sort of plasma—ordinarily known as the fourth condition of issue—which has gas particles show at direct temperature and electrons at moderately high temperatures. The properties of plasma have been widely looked into in the course of recent decades and an extensive number of front line utilizations of cold plasma innovation has exuded. Cold plasma isn't in
Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, …
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants
Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market
ReportsWorldwide has announced the addition of a new report title Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market to its growing collection of premium market research reports. This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for BPH and prostatitis treatment devices. Topics Covered Include: An overview of device-based and pharmacological therapies for BPH and prostatitis. Global and country/region-specific market forecasts, including forecasts by product segment. Competitive analyses
Global Benign Prostatic Hyperplasia Industry Clinical Trials Review, H2, 2016
"The Report Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2016 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" GlobalData's clinical trial report, Benign Prostatic Hyperplasia Global Clinical Trials Review, H2, 2016" provides an overview of Benign Prostatic Hyperplasia clinical trials scenario. This report provides top line data relating to the clinical trials on Benign Prostatic Hyperplasia. Report includes an overview